COAG
Hemab Therapeutics Holdings, Inc. Common Stock
COAG
Hemab Therapeutics Holdings, Inc. Common Stock
COAG
Hemab Therapeutics Holdings, Inc. Common Stock
Hemab Therapeutics is building a differentiated coagulation franchise targeting underserved rare bleeding disorders with a prophylactic approach. COAG's robust cash position post-IPO funds operations
HMB-002 clinical data demonstrate proof of mechanism, with dose-dependent, greater than or equal to 2.4-fold peak increases in Von Willebrand Factor (VWF) and Factor VIII (FVIII), normalization of pea